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A B S T R A C T
The neuronal ceroid lipofuscinoses (NCLs) are lysosomal storage disorders characterized by progressive neu-
rodegeneration and declines in neurological functions. Pathogenic sequence variants in at least 13 genes underlie
different forms of NCL, almost all of which are recessively inherited. To date 13 sequence variants in 8 canine
orthologs of human NCL genes have been found to occur in 11 dog breeds in which they result in progressive
neurological disorders similar to human NCLs. Canine NCLs can serve as models for preclinical evaluation of
therapeutic interventions for these disorders. In most NCLs, the onset of neurological signs occurs in childhood,
but some forms have adult onsets. Among these is CLN12 disease, also known as Kufor-Rakeb syndrome, PARK9,
and spastic paraplegia78. These disorders result from variants in ATP13A2 which encodes a putative trans-
membrane ion transporter important for lysosomal function. Three Australian Cattle Dogs (a female and two of
her offspring) were identified with a progressive neurological disorder with an onset of clinical signs at ap-
proximately 6 years of age. The affected dogs exhibited clinical courses and histopathology characteristic of the
NCLs. Whole genome sequence analysis of one of these dogs revealed a homozygous c.1118C > T variant in
ATP13A2 that predicts a nonconservative p.(Thr373Ile) amino acid substitution. All 3 affected dogs were
homozygous for this variant, which was heterozygous in 42 of 394 unaffected Australian Cattle Dogs, the re-
mainder of which were homozygous for the c.1118C allele. The high frequency of the mutant allele in this breed
suggests that further screening for this variant should identify additional homozygous dogs and indicates that it
would be advisable to perform such screening prior to breeding Australian Cattle Dogs.
1. Introduction
Dogs suffer from many of the same hereditary progressive neuro-
degenerative diseases that occur in humans. Among these are a group of
disorders designated the neuronal ceroid lipofuscinoses (NCLs). In
people these diseases are characterized by apparently normal devel-
opment followed by progressive declines in cognitive and motor func-
tions, loss of vision, seizures, and in most cases premature death [1].
These clinical signs are accompanied by progressive degeneration of the
central nervous system and usually the retina as well. The human NCLs
are designated CLN1 through CLN14 based on the gene in which the
pathological sequence variant occurs. DNA sequence variants that un-
derlie the NCLs occur in at least 13 genes [2] (Table S1). The ages of
onset of clinical signs and the rates of disease progression vary
depending on the gene in which the causative variant occurs and the
nature of the variant [3]. The disease phenotype can vary substantially
with each form of NCL [1]. Onset of disease signs ranges from infancy
to adulthood.
Diseases with clinical signs similar to the human NCLs have been
reported in over 20 dog breeds [4,5]. The causes of the majority of these
canine disorders have been found to be variants in the canine orthologs
of genes associated with human NCLs. To date, sequence variants in 9
canine orthologs of human NCL genes have been associated with NCLs
in dogs [4,5]. Among these are diseases with onset of clinical signs
ranging from a few months to 7 years of age.
Australian Cattle Dogs are one of the breeds affected by NCL for
which a genetic basis has been identified. The disease-causing genetic
variant identified in the breed is a truncating nonsense variant in CLN5
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[6]. This same variant causes NCL disease in Border Collies [7]. The
onset of clinical signs in dogs with this variant becomes apparent
around the age of 12 months and affected dogs reach end-stage disease
with severe neurological signs at 20 to 27 months of age. Three closely-
related Australian Cattle Dogs presented with progressive neurological
signs typical of the NCLs that did not become apparent until the dogs
were approximately 6 years of age with disease progression from onset
to end-stage of up to more than 2 years. None of these dogs had the
CLN5 sequence variant previously associated with NCL in this breed.
Studies were therefore undertaken to determine whether these dogs
suffered from another form of NCL, and to determine whether their
disease was associated with a sequence variant in one of the known NCL
genes.
2. Materials and methods
2.1. Ethics statement
The dogs in this study were examined and blood and tissue samples
were collected with the consent of their owners. The studies were
performed with the approval of the Cantonal Committee for Animal
Experiments (Canton of Bern; permit BE75/16). All animal experiments
were done in accordance with local laws and regulations including the
U.S. National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
2.2. Animals
This study included 397 Australian Cattle dogs. Three closely re-
lated dogs presented clinical signs characteristic of NCL and were de-
signated as cases. These signs are described in detail in the Results
section of this paper. The three affected Australian Cattle Dogs in this
study consisted of a female (dog A) and two offspring from one of her
litters (one male [dog B] and one female [dog C]). Also included is dog
D, the father of dogs B and C. DNA samples from the remaining 393
Australian Cattle Dogs were collected in the context of other ongoing
research projects. They included 26 Australian Cattle Dogs older than 6
years that did not show any signs of neurological disease and 367
Australian Cattle Dogs, for which no phenotype information was
available and which were considered population controls. Samples
which had been donated to the Vetsuisse Biobank from 555 additional
dogs of 70 diverse breeds were also used as controls (Table S2).
Genomic DNA was extracted from whole blood of each of these dogs.
2.3. Disease phenotype characterization
Characterization of the behavioral abnormalities in the three af-
fected dogs was based primarily on information provided by the dogs'
owners on a symptom survey form that has been in use for over 10 years
for identifying dogs with various forms of NCL or by information pro-
vided by the owners in a similar manner. Dog A was euthanized at the
age of 8 years and 2 months due to the progression of disease signs.
Before her death, blood was obtained for DNA isolation, but no tissues
were collected at the time of euthanasia. Dogs B and C were euthanized
at the age of 6 years and 9 months and at 7 years and 7 months re-
spectively due to progression of disease signs, and tissues were collected
at the time of euthanasia, as described below. Dog D lived to the age of
16 years and did not exhibit any behavioral or neurological abnorm-
alities.
At the time of euthanasia, samples of cerebellum, parietal cerebral
cortex, eyes, and heart ventricular wall were collected from dogs B and
C and a section of cervical spinal cord was collected from dog C. From
each dog, one eye and a portion of each other tissue was fixed in 10%
buffered formalin or “immuno fix” (3.5% paraformaldehyde, 0.05%
glutaraldehyde, 120 mM sodium cacodylate, 1 mM CaCl2, pH 7.4), and
the other eye and a portion of each other tissue was fixed in cacodylate-
buffered glutaraldehyde or glutaraldehyde-paraformaldehyde [8]. The
formalin and “Immuno”-fixed tissues were embedded in paraffin or
Tissue-Tek embedding medium (Sakura Finetek, Tokyo, Japan) and
sections were cut and stained as described in the Results section. Im-
munostaining of paraffin sections for the lysosomal marker LAMP1 was
performed with a polyclonal rabbit anti-LAMP1 primary antibody
(Abcam ab24170) using previously described techniques [9]. In addi-
tion, unstained sections of the paraffin-embedded samples were de-
paraffinized and examined unstained with fluorescence microscopy as
described previously, as were cryosections of the Tissue-Tek embedded
samples [10]. Cryoscections of cardiac muscle samples were also ex-
amined after staining with the lipid dye Sudan Black III and counter-
staining with Mayer's Hematoxylin. Portions of the glutaraldehyde-
fixed tissues were post-fixed in osmium tetroxide, embedded in epoxy
resin and 70 to 90 nm thick sections were cut from the embedded
samples. The sections were collected on 200 mesh thin-barred copper
grids, stained with uranyl acetated and lead citrate, and were then
examined and photographed with a JEOL 1400 transmission electron
microscope equipped with a Gatan digital microscope. Sections of the
resin-embedded tissues were also cut at a thickness of 0.4 to 0.8 μm,
mounted on glass slides, stained with toluidine blue, and photographed
with conventional transmitted light microscopy.
2.4. Reference sequences
All analyses were performed using the dog CanFam 3.1 genome
assembly as reference sequence. Numbering within the canine
ATP13A2 gene refers to NCBI RefSeq accessions XM_005617949.3
(mRNA) and XP_005618006.1 (protein). Numbering within the
human ATP13A2 gene refers to NCBI RefSeq accessions NM_022089.3
(mRNA) and NP_071372.1 (protein).
2.5. Whole genome resequencing and variant filtering
An Illumina TruSeq PCR-free library with an insert size of 350 bp
was prepared from one affected Australian Cattle dog (dog B) and 195
million 2 × 150 bp paired-end reads were obtained on an Illumina
HiSeq 3000 instrument (21.6× coverage). Mapping and variant calling
was done as described [11]. The sequence data were deposited under
study accession PRJEB16012 and sample accession SAMEA104500413
at the European Nucleotide Archive. Functional effects and genomic
context of the called variants were annotated using SnpEff software
[12] together with the NCBI Canis lupus familiaris Annotation Release
104. For private variant filtering we used control genome sequences
from 8 wolves and 209 dogs. These genomes were either publicly
available [13] or produced during other previous projects in our la-
boratory (Table S3).
2.6. DNA extraction, PCR and Sanger sequencing
Genomic DNA was extracted from EDTA blood samples using the
Maxwell RSC Whole Blood DNA Kit in combination with the Maxwell
RSC machine (Promega). We used a Sanger sequencing protocol for
targeted genotyping of the ATP13A2:c.1118C > T variant.
Specifically, a 593 bp PCR product was amplified from genomic DNA
using the AmpliTaqGold360Mastermix (Life Technologies) together
with primers 5‘-GAT GCC TGC ATG TAT GGT TG-3‘ (forward) and 5‘-
GTG GGC GGT TTC ACT TTT TA-3’ (reverse). After treatment with
exonuclease I and alkaline phosphatase, amplicons were sequenced on
an ABI 3730 DNA Analyzer (Life Technologies). Sanger sequences were
analyzed with the Sequencher 5.1 software (GeneCodes).
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3. Results
3.1. Characterization of disease phenotype
The onset of neurological signs in the affected dogs occurred at
approximately 6 years of age and progressively worsened over time.
Among the disease-related signs reported by the dogs' owners were
anxiety, impaired ability to recognize and respond to previously
learned commands, increased sensitivity to loud or unexpected sounds,
sleep disturbances, inappropriate or persistent vocalization, impaired
ability to navigate stairs and to jump up or down from furniture,
trembling, seizures, stiffness or weakness, loss of coordination, and
ability to see in both bright and dim light. In addition to these signs,
neurological examination findings in affected dog C included hy-
persensitivity to tactile stimuli, clumsiness, a broad-based stance in the
pelvic limbs, mild ataxia, unsteady gait on slippery surfaces, inter-
mittent pacing gait, hopping gait in pelvic limbs while trotting, reduced
palpebral reflex and reduced menace response in both eyes, normal
pupillary light reflexes in response to bright stimuli, and decreased
nasal sensation. In addition, the affected dog that underwent a neuro-
logic exam exhibited slightly delayed proprioception in the pelivic
limbs, delayed and reduced hopping in all 4 limbs, and reduced ex-
tensor postural thrust. Spinal reflexes were normal. Dog B was eu-
thanized at age 6 years and 9 months, and his littermate dog C was
euthanized at age 7 years and 8 months due to the progression of these
signs. Dog A, the mother of dogs B and C, was euthanized at age 8 years
and 2 months. In addition to exhibiting the signs described above, she
became very aggressive starting at about 8 years of age to the point of
being dangerous, even toward her owner, and euthanasia was elected
for this reason. Dog D, the father of dogs B and C, lived to be 16 years of
age without exhibiting any of these behavioral abnormalities.
Although the behavioral signs exhibited by the affected dogs are
consistent with the canine NCLs, other causes are possible, including
other inherited neurological diseases or brain tumors. A universal
characteristic of both canine and human NCLs is the progressive ac-
cumulation of autofluorescent lysosomal storage bodies in cells of the
central nervous system, as well as many other tissues [1]. The presence
of these storage bodies can be used to distinguish the NCLs from other
neurological disorders. Therefore, unstained sections of brain, retina,
and heart from affected dogs B and C were examined for the presence of
these characteristic autofluorescent storage bodies.
The cerebellum of dogs B and C exhibited massive accumulations of
autofluorescent storage bodies primarily in the Purkinje cell layer, the
meninges and large neurons in the deep cerebellar nuclei (Fig. 1). These
autofluorescent aggregates were also present to a lesser extent in the
molecular layer of the cerebellar cortex. In the Purkinje cell layer au-
tofluorescent inclusions were abundant within the perinuclear areas of
the Purkinje cells (Fig. 1A), as well as in clumps much larger than ty-
pical Purkinje cell bodies (Fig. 1 B). Abundant autofluorescent storage
material was also present in the cerebellar meninges (Fig. 1C). Massive
accumulations of the storage bodies in the deep cerebellar nuclei were
localized to the perinuclear regions of large neurons (Fig. 1D).
In the cerebral cortex of both affected littermates, autfluorescent
storage material was present in almost all neurons (Fig. 2). This ma-
terial appeared as aggregates of small granules in the perinuclear re-
gions of the cells. When the neurons were cut in the appropriate plane
of section, these aggregates could be seen to be concentrated in one
region of the cell body rather than being evenly distributed throughout
the cell (Fig. 2B). Neurons in both the ventral and dorsal horns of the
cervical spinal cord of dog C contained massive amounts of auto-
fluorescent storage material (Fig. 3). As in other forms of canine NCL,
disease-specific autofluorescent material was observed in retinal
ganglion cells and along the outer limiting membrane from affected dog
C (Fig. 4A). At the electron microscopic level, the storage material in
the ganglion cells consisted on membrane-bounded inclusions con-
taining whorls of condensed membrane-like structures sometimes
embedded in a granular matrix (Fig. 4).
As in some other forms of canine NCL, strands of autofluorescent
storage bodies were present between the muscle fibers of the cardiac
muscle (Fig. 5A). Based on their location and topography, it appears
that these storage bodies are located in the cardiac Purkinje fibers.
Substantial aggregates of autofluorescent storage bodies were also
present in the neurons of cardiac ganglia (Fig. 5B).
The ultrastructural appearances of the disease-related cellular in-
clusion bodies in the tissues of affected dog B were quite distinctive. In
the cerebellar Purkinje layer, these consisted of membrane-bounded
structures as large as 4 to 5 μm in diameter (Fig. 6). The contents of
most of these inclusions consisted primarily of whorls and stacks of
Fig. 1. Fluorescence micrographs unstained sections of the cerebellar Purkinje
cell layer (A and B), the cerebellar meninges (C), and a deep cerebellar nucleus
(D) from dog C. Massive accumulations of yellow-emitting autofluorescent
material was present primarily in these areas of the cerebellum. Bar in (A) in-
dicates the magnification of a 4 micrographs. In (A) p = Purkinje cell;
m = molecular layer; g = granule cell layer. (For interpretation of the refer-
ences to colour in this figure legend, the reader is referred to the web version of
this article.)
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membrane-like structures (Fig. 6A). However the contents of some in-
clusion bodies consisted largely of curvilinear material similar that
which is characteristic of the storage material typical of the CLN12 form
of NCL (arrows in Fig. 6A). A small minority of the inclusion bodies in
the cerebellum consisted of tightly packed fine membrane-like material
that was randomly oriented (arrowhead in Fig. 6B).
The contents of the membrane-bounded disease-related inclusions
in cerebral cortical neurons of the affected dogs consisted primarily of
clusters of membrane-like structures, much like those in the cerebellum
(Fig. 7). However, for the most part these clusters did not occur in the
whorl-like arrangements observed in the cerebellum. The sizes and
shapes of the individual inclusion bodies were variable and range about
3 to as much as 20 μm in diameter. No inclusions with curvilinear
contents were observed in the cerebral cortical samples, but some of the
storage bodies contained scattered dark amorphous inclusions that
were 0.5 to 1 μm in diameter.
The ultrastructural appearances of the disease-related auto-
fluorescent inclusions of the cardiac muscle from the affected dog were
quite different from those of the inclusions present in the brain. The
disease-related inclusions in the cardiac muscle consisted of tightly-
packed aggregates of membrane-bounded rounded structures and
structures that appear to have been round but to have been compressed
into other shapes by crowding from the surrounding inclusion bodies
(Fig. 8). These inclusions consisted of a mixture of two distinctly dif-
ferent types based on the appearance of their contents. The contents of
some of the storage bodies had a uniform electron-dense appearance
with no structural detail. The contents of the remaining inclusions
consisted of uniform flocculent material. The two types of inclusions
were randomly intermixed and ranged in size from less than 0.2 μm to
greater than 6 μm. No nerve ganglia were present in the cardiac samples
that were preserved for electron microscopic examination.
The ultrastructural appearances of the uniformly electron dense
structures within the cardiac muscle inclusions are typical of lipid
droplets [14]. Indeed, these structures stained with the lipid stain
Sudan Black III in cryostat sections of cardiac muscle (Fig. 9A), whereas
the disease-related inclusion bodies in neural tissues did not stain with
this dye. Within the inclusions in the heart, a subset of the granular
particles stained with the periodic acid-Schiff (PAS) reagent, which is
specific for the carbohydrate moieties of polysaccharides, glycopro-
teins, and glycolipids (Fig. 9B). The staining pattern in the heart sug-
gested that only the structures with flocculent material and not the lipid
droplet-like structures contained carbohydrate components. The dis-
ease-specific inclusions in the cardiac muscle also exhibited LAMP1
immunostaining (Fig. 9C) indicating that these inclusions were derived
from lysosomes. The disease-specific cellular inclusion bodies in cere-
bral cortex and cerebellum also stained strongly with PAS, but those in
the retina did not (data not shown). As with the cardiac muscle, the
disease-specific cellular inclusions in the cerebral cortex, cerebellum
and retinal ganglion cells stained with an anit-LAMP1 antibody
(Fig. 10), suggesting that these inclusions were also derived from ly-
sosomes.
In addition to exhibiting a characteristic autofluorescence, the sto-
rage material that accumulates in many of the NCLs has been shown to
stain with Luxol fast blue in paraffin sections [15–17]. This was also the
case for the storage bodies in every tissue from affected dog B that was
examined (Fig. 11). Within the Purjkinje cell layer were clusters of cells
variable in shape and size that were filled with autofluorescent material
(Fig. 1B) that stained intensely with Luxol fast blue (g in Fig. 11B).
These cells may be microglia-derived phagocytic cells (gitter cells) that
have taken up large amounts of storage material that originated in
Purkinje cells that have degenerated. Non-Purkinje cells in or near the
Purkinje cell layer that contain disease-related storage material have
been reported in other forms of canine NCL [6,18], and a similar
clustering of these cells in the Purkinje layer of the cerebellum occurs in
at least one of these other NCLs [6]. Whether these cells represent
phagocytic cells that have taken up storage material originally gener-
ated in Purkinje cells remains to be determined.
In earlier-onset forms of canine as well as human NCL, the diseases
are characterized by pronounced astrogliosis [6,18–21]. Im-
munostaining (IHC) of brain and retinal tissues of the affected Aus-
tralian Cattle Dogs for glial fibrillary acid protein (GFAP), a marker for
reactive astrocytes, indicated that astrogliosis is also a prominent fea-
ture of this late-onset disease, although not in the cerebellar cortex
(Figs. 12 and 13). In addition, pronounced GFAP immunostaining was
observed in small number of cells adjacent to large blood vessels in
heart ventricular muscle and surrounding large blood vessels in the
inner retina (Fig. 13).
Fig. 2. Fluorescence micrographs of unstainded sections of the parietal cerebral
cortex of dog B. Autofluorescent storage material was present in almost all of
the cerebral cortical neurons, and in the larger neurons could be seen to be
localized within the perinuclear region of the cells (B). Bar in (B) indicates the
magnification of both micrographs.
Fig. 3. Fluorescence micrographs of the ventral (A) and dorsal (B) horns of an unstained section of cervical spinal cord from dog C showing massive accumulations of
autofluorescent storage material in neurons throughout the spinal cord gray matter. Bar in (B) indicates the magnification of both micrographs.
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3.2. Genetic analysis
We performed whole genome sequencing on one affected offspring
and searched for private heterozygous and homozygous protein-chan-
ging variants in the case by comparing them with genome sequences
from 8 wolves and 209 dogs from genetically diverse breeds (Table S3).
We did not have any specific information regarding a potential NCL
phenotype in the controls. However, as this is a rare condition, we as-
sumed the control dogs and wolves to be homozygous wildtype at the
causative variant.
The variant calling pipeline detected 4,028,278 variants in the
genome of the sequenced case. Of these, 151 were absent from the
control genomes and predicted to be protein-changing. We prioritized
13 known candidate genes, which had previously been identified in
human and animal neuronal ceroid lipofuscinoses (Table S1). Only one
variant was located in one of these candidate genes (ATP13A2), while
the other 150 were in genes that we did not consider to be likely
functional candidate genes (Table 1; Table S4). The ATP13A2 variant
was a missense variant, XM_005617949.3:c.1118C > T, predicted to
result in a non-conservative exchange of a threonine into an isoleucine,
XP_005618006.1:p.(Thr373Ile). The predicted amino acid substitution
is located in the cytoplasmic E1-E2 ATPase domain (pfam00122). The
wildtype threonine is conserved in ATP13A2 orthologs across phylo-
genetically diverse vertebrates (Fig. 14).
We then genotyped the variant in a cohort of 397 Australian Cattle
Dogs, which included the 3 known cases, dog D, 26 unaffected
Australian Cattle Dogs older than 6 years of age and 367 population
controls. This revealed a perfect association of the genotypes with the
phenotype (Table 2). All three affected dogs carried the variant in
homozygous state. Dog D, the sire of the two affected dogs was het-
erozygous (obligate carrier). Among the other 393 Australian Cattle
dogs, we observed 352 dogs that were homozygous wildtype and 41
dogs that were heterozygous and presumably carriers for the disease.
These data indicate that among the Australian Cattle Dogs that were
sampled, the carrier frequency is around 10%. Because of sampling bias
in our population, the carrier frequency among all Australian Cattle
Dogs may be different. We also genotyped 555 dogs from genetically
diverse breeds. None of these dogs carried the ATP13A2:c.1118C > T
variant (Table S2).
4. Discussion and conclusions
A human autosomal recessive neurological disorder originally
named Kufor-Rakeb syndrome (KRS) was first described in 1994 in
members of a consanguineous Arabic family in which five siblings were
affected [22]. The disease name was based on the name of the region in
Jordan where the family resided. The onset of disease signs occurred at
12 to 16 years of age and progressively worsened over time resulting in
severe impairment of motor and cognitive functions within 2 years of
onset. Initial signs were abnormal facial expressions and progressive
slowing of all motor functions. The disease progression is characterized
by development of levodopa-responsive parkinsonism (severe akinesia
and rigidity), supranuclear upgaze paresis, constant drooling, speech
impairment, and dementia. The most severely affected individuals were
bedridden with a generalized flexed posture. All of the affected siblings
had normal visual acuity and no retinal abnormalities were observed
with fundoscopy. Significant atrophy of the globus pallidus and the
pyramids, as well as generalized brain atrophy in later stages of disease
progression were documented with magnetic resonance imaging. The
disease was quite slow, but ultimately affected individuals died as a
result of profound neurological decline. There was significant varia-
bility in the severity of clinical signs between the affected siblings. A
causal genetic variant for this disorder was found to be a 22 bp deletion
Fig. 4. (A) Fluorescence micrograph of un-
stained section of the retina from dog C.
Autofluorescent material was present in the
cell bodies of the ganglion cells (arrows)
and small punctate autofluorescent bodies
were present along the outer limiting
membrane (olm). (B) Electron micrograph
of disease-sepdific storage bodies (s) in a
retinal ganglion cell from dog C.
Abbreviations: GCL. ganglion cell layer; IPL,
inner plexiform layer; INL, inner nuclear
layer; ONL, outer nuclear layer; OLM, outer
limiting memberane; POS, photoreceptor
outer segments.
Fig. 5. Fluorscence micrographs of sections of cardiac ventricular wall from
affected dog B. Strands of autofluorescent granules were present along the
cardiac muscle fibers arranged parallel with the longitudinal orientation of
muscle fibers (A). Aggregates of autoflurescent inclusions were also present in
neurons of cardiac ganglia (B). Bar in (A) indicates the magnification of both
micrographs.
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in exon 16 of ATP13A2 [23].
Subsequently, over 140 sequence variants in the coding regions of
ATP13A2 have been identified in people, many of which have been
reported to pathogenic (https://www.ncbi.nlm.nih.gov/clinvar)
[11,24–31]. Many of the pathogenic variants predict single amino acid
changes in the protein, although partial deletions and splice site var-
iants associated with neurological disease have also been identified
[32]. Among the clinical diagnoses associated with these variants, are
NCL (CLN12, OMIM 610513), a Parkinsonian-like disorder designated
PARK9, and spastic paraplegia78 (OMIM 617225) [33]. Interestingly,
the latter authors found that a sequence variant in another NCL gene,
TPP1, also resulted in spastic paraplegia that was responsive to L-DOPA.
This represents one of a number of overlaps between phenotypes as-
sociated with ATP13A2 variants and variants in other NCL genes and
supports the classification of ATP13A2 pathogenic variants as NCL
types. In most cases of neurologic disease associated with a variety of
ATP13A2 sequence variants, at least some of the signs were typical of
recognized NCL disorders, including diffuse brain atrophy, myoclonus,
progressive cognitive decline, tremor, hallucinations, and behavioral
abnormalities. For more detailed information and citations to relevant
publications, see OMIM entry 610,513.
The spectrum of clinical signs associated with these mutations
varies both among individuals homozygous for the same variant and
between indivuals with different variants in ATP13A2 [34–36]. The
bases for this heterogeneity in clinical signs is unknown, but differences
in ages of disease onset, progression, and clinical signs among
Fig. 6. Electron micrographs of disease-related inclusion bodies in the cerbellar
Purkinje layer from affected dog B. Individual membrane-bound inclusions
occurred in tightly-packed clusters. The contents of the majority of the inclusion
bodies consisted of whorls and stacks of membrane-like structures (A), but the
contents of some inclusionbodies consisted primarily of curvilinear structures
(arrows in B) or of tighlty-packed fine membrane-like material (arrowhead in
B).
Fig. 7. Electron micrograph showing disease-related inclusion in a neuron from
the parietal cerebral cortex of affected dog C.
Fig. 8. (A) Light microgaph of a large cluster of inclusion bodies in the cardiac
muscle the heart ventricle of affected dog B. (B) Electron micrgraph of the same
type of inclusion bodies in cells adjacent to the cardiac muscle fibers of affected
dog B.
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individuals homozygous for the same variant suggest that other genetic
differences modulate the effects of abnormalities in or absence of
ATP13A2. Environmental factors are less likely to play a significant role
in this heterogenity, since the disease pheontype can vary significantly
among siblings.
Given the variability in phenotypes associated with different mu-
tations or even with the same variant in ATP13A2 [29], one may be
tempted to assign subsets of the disorders resulting from variants in this
gene to either the NCLs, Parkinsonian disorders, spastic paraplegias, or
other groups depending on the phenotype, but in some cases this would
result in siblings with the same variant but different phenotypes being
classified as having different diseases. On the other hand, it has become
the convention in the NCL field to classify diseases in this group by the
gene in which the variant occurs rather than by disease phenotype. This
makes sense with respect to understanding the primary disease me-
chanisms and potential approaches to therapy. Therefore, because of
the variability in phenotypes among patients with ATP13A2 variants,
there is an advantage to grouping these disorders together under one
designation based on the gene in which the causal variants occur, which
we propose to be the currently accepted CLN12. As with the other NCL
types, one can differentiate patients within the overall NCL groups as
being “variants” of CLN12 based on phenotype. We discourage con-
tinued use of the disease names KRS, PARK9, and spastic paraplegia78
because it would be cumbersome and not particularly helpful to use a
separate disease name for each different pathogenic ATP13A2 variant.
Rather, we encourage future use of CLN12 to designate all disorders
resulting from pathogenic variants in ATP13A2, with the addition of
descriptive terms related to phenotype to describe subtypes of these
disorders. This practice is well established in the NCL field for all forms
of NCL, so for consistency, should be applied to all disorders resulting
from pathogenic variants in ATP13A2.
The function of the protein or proteins encoded by ATP13A2 has not
been firmly established. There is evidence that the ATP13A2 protein is a
lysosomal transmembrane ATPase ion pump that appears to be a Zn2+
transporter [30,31,37–40]. Variants that are predicted to alter the
function of ATP13A2 result in lysosomal dysfunction and the accumu-
latiuon of lysosomal storage bodies [11,37,40–42], as well as altering
other celluluar functions including endosomal trafficking and functions
that either depend on intracellular zinc homeostasis or are secondary to
lysosomal dysfunction [34–36]. However, experimental evidence also
suggests that ATP13A2 plays a direct role in mitochondrial bioener-
getics, autophagy, α-synuclein metabolism, and endosome-mediated
cargo sorting [29,34–36,39,43,44]. Different pathological variants in
human ATP13A2 have different effects on the protein, including its
complete absence, impaired ATPase activity, mislocation within the
cell, enhanced proteosomal degradation, and increased protein stability
[31]. Which of these effects are associated with the Australian Cattle
Dog p.(Thr373Ile) variant remain to be determined.
The neuronal ceroid lipofuscinoses (NCLs) are a group of inherited
Fig. 9. Light microgaphs of sections of heart ventricle cardiac muscles from an
affected dog stained with Sudan black III (A), periodic acid Schiff reagent (B),
and immunostainded with an anti-LAMP1 antibody. Arrows indicate disease-
related inclusion bodies.
Fig. 10. Light microgaphs of paraffin sections of cerebral cortex (A), cerebelum
(B) and retina (C) from an affected dog. Sections were immunostained with an
antibody against the lysosomal marker LAMP1. Inclusion bodies in cerebral
cortical neurons (arrows in A), cerebellar Purkinje cells (arrows in B), and
retinal ganglion cells (arrows in C) stained with the anti-LAMP1 antibody. Bar
in B indicates magnification of all 3 micrographs.
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progressive neurodegenerative disorders that are characterized by
normal development followed in most cases by progressive declines in
cognitive and motor functions, loss of vision, seizures, brain atrophy,
retinal degeneration, and a generalized accumulation of auto-
fluorescent lysosomal storage bodies throughout the central nervous
system and in many other tissues [1]. Variants in at least 13 genes
underlie different forms of NCL [2]. Naturally occurring NCLs have
been described in many dog breeds, and the genetic bases for these
disorders have been identified in genes orthologous to those associated
with human NCLs [4,5]. A late-adult onset form of NCL in Tibetan
Terriers was found to result from a truncating single base deletion in
ATP13A2 [45]. This deletion was associated with exon skipping in af-
fected dogs [46]. These discoveries led to a re-evaluation of KRS as-
sociated with ATP13A2 variants and its classification as an NCL with
the designation of CLN12 [47]. The basis for this classification, in ad-
dition to the similarity in clinical signs and progressive neurodegen-
eration, is the finding that like other NCLs, individuals that are
homozygous for variants in ATP13A2 exhibit accumulation of auto-
fluorescent lysosomal storage bodies with ultrastructural features
characteristic of the NCLs.
Unlike the variability in clinical sigs in human subjects with neu-
rological diseases associated with ATP13A2 sequence variants, even
between siblings homozygous for the same variant, the disease signs
and progression among Tibetan Terriers with CLN12 disease due to a
single base deletion in ATP13A2 were quite uniform [45]. The age of
onset is approximately 7 years of age and neurological signs in most
affected dogs progress to the stage at which euthanasia is elected at
approximately 10 years of age. The clinical signs associated with the
Tibetan Terrier disease only partially overlap those of human subjects
with ATP13A2-related disease. The canine disease is characterized by
anxiety, aggression, cognitive decline, loss of coordination, ataxia,
tremors, seizures (primarily near disease end-stage), and progressive
vison loss in both dim and bright lighting. Unlike most human subjects
with ATP13A2-related disorders, Tibetan Terriers with CLN12 disease
exhibited pronounced retinal degeneration and impaired retinal func-
tion [48].
The Tibetan Terrier disease resulted from a single base deletion
(frameshift) that would be expected to result in a complete lack of
ATP13A2 protein, whereas the mutant allele in the Australian Cattle
Dogs is predicted to encode a p.(Thr373Ile) amino acid substitution in
Fig. 11. Luxol fast blue stained paraffin sections of cerebral cortex (A), cerebellar cortex (B), ciliac ganglion (C), thalamus (D), retina (E), and cardiac muscle. Arrows
indicate specific Luxol fast blue staining. In panel (B) the staining is apparent in both the Purkinje cells (p) and the large non-Purkinje cell aggregates in the Purkinje
cell layer (g). In panel (E) the stained cells indicated by arrows are retinal ganglion cells. In the cardiac muscle the specific staining could be seen despite relatively
high backgound staining in this tissue. In all cases, the localization of the stained inclusions was the same as the autofluorescence in unstained sections. Bar in (A)
indicates the magnification of panels (A-E). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article.)
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ATP13A2. Because the wildtype threonine is conserved in ATP13A2
orthologs across phylogenetically diverse vertebrates, and replacement
of threonine by isoleucine at p.373 results in a disease phenotype very
similar to that of Tibetan Terriers with the ATP13A2 single base dele-
tion, it appears likely that Australian Cattle Dog missense variant alters
an important functional domain of the protein. This is consistent with
the fact that the age of onset was earlier and the rate of disease pro-
gression was faster in the Australian Cattle Dogs than that in Tibetan
Terriers with the truncating variant. Because the affected Australian
Cattle Dogs are expected to produce a dysfunctional form of ATP13A2,
biochemical analyses of tissues from dogs with this mutation may lead
Fig. 12. GFAP IHC stained sections of cerebellar cortex (A), a deep cerebellar
nucleus (B), and the parietal cerebral cortex from affected dog C. No significant
astrogliosis was observed in the cerebellar cortex, moderate astrogliosis was
present in the deep cerebellar nuclei (B), and pronouced astrogliosis was pre-
sent in the cerebral cortex (C). Purkinje cells were sparse in the cerbellum of
dog B, but structures resembling the clusters of autoflourescent cells were
present in the Purkinje layer (arrow in A). Purkinje cell densities were greater in
Dog C. Aggregates of hematoxylin-stained material were present in the cell
bodies on large neurons in the deep nuclei of the cerebellum (arrowheads in B).
Bar in (C) indicates the magnification of all 3 micrographs.
Fig. 13. GFAP IHC stained sections of cervical spinal cord ventral horn (A),
cervical spinal cord dorsal horn (B),retina (C), and large cardiac ventricular
muscle blood vessel from affected dog C. Significant astrogliosis was observed
throughout the spinal cord gray matter (A and B) and in the retinal ganglion cell
layer (C). GFAP-stained cells were also observed adjacent to blood vessels in the
cardiac ventricual wall muscle (D). Bar in (A) indicates the magnification of all
4 micrographs.
Table 1
Variants detected by whole genome resequencing of an affected Australian
Cattle Dog.
Filtering step Variantsa
Variants in whole genome 4,028,278
Private variants in the whole genomeb 20,975
Private protein changing variants in the whole genome 151
Private protein changing variants in 12 candidate genesc 1
a Only variants which passed the GATK quality filter were counted.
b Private variants were exclusively present in the affected dog and had
homozygous reference or missing genotype calls in 217 control genomes.
c ATP13A2, CLN3, CLN5, CLN6, CLN8, CTSD, CTSF, DNAJC5, GRN, MFSD8,
PPT1, TPP1 (Table S1).
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to a better understanding of the normal function of this protein. The
predicted amino acid substitution is located in the cytoplasmic E1-E2
ATPase domain, suggesting that this variant may alter an important
function of this protein. Assessment of this possibility can be achieved
by analyzing tissues obtained from dogs with this variant. As noted
earlier, however, human subjects with single amino acid substitutions
at many dispersed locations in APT13A2 have similar progressive
neurological disease, so it appears that most domains of the protein are
important for its normal functioning.
The disease-related inclusion bodies that accumulated in neurolo-
gical tissues were similar in both Tibetan Terriers and Australian Cattle
Dogs with late-onset NCL. Membrane-bound autofluorescent inclusions
(lipofuscin) also accumulate in many postmitotic cells during normal
aging. However, the ultrastructural features of the disease-related in-
clusions were quite distinct from those of lipofuscin, both in nervous
tissues and in the heart [14,49–61]. The disease-related inclusions in
cardiac muscle of the affected dogs were quite unique and differed
substantially from those in the brain and retina (Fig. 8). These inclu-
sions consisted of a mixture of round bodies with contents that had
either uniform electron density or a flocculent appearance. Based on
their staining properties, uniformly stained bodies appear to be lipid
droplets, whereas material within the bodies that co-localize with them
appear to have carbohydrate moieties. Cardiac muscle pathology has
not been studied extensively in the NCLs, so it would be of interest to
determine whether similar inclusions accumulate in the hearts of
people and dogs with all of the various forms of NCL. The disease-re-
lated storage material that accumulates in all cell types that were ex-
amined in the affected dogs were stained with an antibody that speci-
fically labels the lysosomal marker protein LAMP1. Therefore, these
cellular inclusions can be classified as lysosomal storage bodies.
Although only two littermate Australian Cattle Dogs and their mo-
ther have been identified that are homozygous for the mutant allele, a
screen of 394 other Australian Cattle Dogs with no known close re-
lationship to the affected dogs identified 42 dogs that were hetero-
zygous for the variant, but no other homozygotes (Table 2). It is
somewhat unexpected that with such a high carrier frequency, no dogs
homozygous for the mutant allele were identified in the population
sample. However, now that a fair number of heterozygotes have been
identified, it should be possible to identify additional homozygous
mutant dogs by selectively screening relatives of the carrier dogs for the
mutant allele. Identification of additional affected dogs by such
screening should open the possibility of obtaining tissues and cell lines
to study ATP13A2 function, and in particular the function of the region
of the protein modified by the p.(Thr373Ile) variant. Affected dogs
identified by genetic screening may also serve as a model for preclinical
therapeutic intervention studies for CLN12 disease. While the late onset
of disease signs makes use of affected Australian Cattle Dogs impractical
as a laboratory model for CLN12 disease, therapeutic studies could be
conducted by recruiting privately owned dogs for treatment studies.
Such studies could provide preclinical data necessary for the conduct of
human clinical trials for treatments for human CLN12 disease.
With respect to preventing the propagation of NCL in Australian
Cattle Dogs, the relatively high incidence of the disease allele in the
population tested indicates that it would be advisable to test dogs in the
general population for the presence of this allele before using them for
breeding. Because of the late onset of clinical signs, this is the only
practical means by which to reduce the disease frequency in the breed.
As would be expected, such screening for the disease alleles associated
with a number of inherited diseases in purebred dogs has been effective
in reducing the frequencies of these alleles and the associated diseases
over time [62–66]. However, in cases where the frequency of the de-
leterious sequence variant is very high, it is important that maintaining
genetic diversity within the breed be considered. In these cases, the best
choice may be to continue to breed heterozygotes with dogs that are
homozygous for the wildtype allele.
As with human CLN12 disease, relative to species lifespan the onset
of clinical signs was later and the rate of disease progression slower in
dogs with ATP13A2-related NCL than in most other forms of NCL [4].
Based on the known functions of the gene product in many of the other
NCLs, the reason for the late onset of CLN12 disease is not clear, par-
ticularly since all of the known NCLs appear to result in impaired ly-
sosomal function. The reason for this may become apparent with fur-
ther study of the Australian Cattle Dog disease, particularly now that
affected dogs can be identified by genetic screening prior to the onset of
clinical signs. The relatively late onset of clinical signs in the canine and
human forms of the disease means that with early detection via genetic
screening there is a large time window during which therapeutic in-
terventions may be undertaken that would prevent or delay disease
onset and progression.
Fig. 14. Details of the ATP13A2:c.1118C > T variant. (A) Sanger electro-
pherograms from dogs with the three different genotypes confirm the presence
of the variant. (B) A multiple species alignment of the ATP13A2 amino acid
sequence illustrates that the variant affects a highly conserved region of the
protein. The wildtype threonine is perfectly conserved across diverse verte-
brates.
Table 2
Association of the ATP13A2:c.1118C > T genotypes with neuronal ceroid li-
pofuscinosis.
Genotype C/C C/T T/T
Affected Australian Cattle Dogs (n= 3) – – 3
Australian Cattle Dogs, unaffected or population controls
(n= 394)
352 42 –
Dogs from other breeds 555 – –
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